Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis
about
The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphismsUsefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic reviewSoluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of ViewCirculating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed CandidatesA circulating permeability factor in focal segmental glomerulosclerosis: the hunt continuesUrokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosisUrokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndromePlasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in miceUtility of the plasma level of suPAR in monitoring risk of mortality during TB treatmentSoluble urokinase-type plasminogen activator receptor levels in patients with schizophreniaDetection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patientsThe urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune system.Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center reportParticipation of the urokinase receptor in neutrophil efferocytosis.uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis.Phosphocitrate is potentially a disease-modifying drug for noncrystal-associated osteoarthritisThe Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders.The mRNA expression of soluble urokinase plasminogen activator surface receptor in human adipose tissue is positively correlated with body mass index.Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.The intriguing role of soluble urokinase receptor in inflammatory diseases.Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.A New Explanation of Inflammation in Rheumatoid Arthritis Patients With Respect to Claudin-5, Matrix Metalloproteinase-9, and Neuroserpin
P2860
Q21261761-B5AA31FF-A9AD-4618-8CF6-759A4E5E368EQ24614787-C7D507DE-6C1B-4559-80C1-11F793AD4BFAQ26738374-C8925BF7-3B9A-42A9-82F9-0D821A97F8F8Q26747221-83122272-116E-4509-9C2E-8117D7D0D091Q26776389-1F3A5DA6-4148-400E-81A9-EB57269A89C0Q31506532-FE9998D2-4E37-440A-AF5F-456647CAD6EBQ33284948-655918CF-AC90-410B-99F4-D3C228C2C046Q33783271-5D18732D-3AA1-43AD-BE01-6169A71EE685Q34032235-51F0F258-6E38-4D67-BA61-8DAA7DC8F56FQ34383596-27A3FB28-B21E-4E1D-B392-3AC6160AF1DDQ34399577-CC8CD418-80AB-425A-85F4-8B39B56A5D81Q35369617-38734F6F-FA23-424D-99B7-CF6EB1B64833Q35534951-6D9B93C3-4372-47FC-BA11-4E8FD39CA52FQ35567020-C49D43E5-7BD0-4CA1-9B0B-3B769F163987Q36046670-C3890FDE-E6F8-4928-B7E7-EFC10C55A755Q36549551-9BF540CB-0EC9-45BD-9FF1-308CB92AFF5AQ37065608-EA100A2D-849F-41EA-8412-13377D776763Q37275898-3D8027E5-555E-426A-A60F-7B0424717BEAQ38721188-D0DF428F-1A62-4C10-8C27-C0E8D164C474Q42019123-4481099B-77CE-458B-A5BA-7D616BDA3F13Q42378691-9D4415B5-1480-4122-9759-384FE7727999Q42777313-1D71DADE-733D-4187-9BF0-9D7332BD3275Q44148383-0F261570-101E-4DA9-AD2D-9B88621D0478Q49124480-D666212D-2EA1-4EB7-9606-878723A89AE1Q50067342-807ABBBB-3116-4E79-90EB-7E684E5F0DF9Q58134749-C6D55684-F39B-4073-A6BD-866F7DE738E7
P2860
Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Soluble urokinase plasminogen ...... ations in rheumatoid arthritis
@ast
Soluble urokinase plasminogen ...... ations in rheumatoid arthritis
@en
type
label
Soluble urokinase plasminogen ...... ations in rheumatoid arthritis
@ast
Soluble urokinase plasminogen ...... ations in rheumatoid arthritis
@en
prefLabel
Soluble urokinase plasminogen ...... ations in rheumatoid arthritis
@ast
Soluble urokinase plasminogen ...... ations in rheumatoid arthritis
@en
P2093
P2860
P356
P1476
Soluble urokinase plasminogen ...... ations in rheumatoid arthritis
@en
P2093
P2860
P304
P356
10.1136/ARD.58.8.488
P407
P577
1999-08-01T00:00:00Z